Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Read More →
Baricitinib 4 mg (Barigen)
Disclaimer: Before purchasing any medicine, always verify whether there is a valid drug license.
Barigen 4 mg contains baricitinib, an oral Janus kinase (JAK) inhibitor that affects signaling pathways involved in inflammation and immune-system activity. Baricitinib is a small-molecule immunomodulatory medicine that works by inhibiting selected JAK enzymes involved in cytokine signaling.
The medical uses of baricitinib vary according to the country, regulatory authorization, patient’s age, medical condition, disease severity and previous treatment. It has been authorized in different jurisdictions for conditions including rheumatoid arthritis, atopic dermatitis, severe alopecia areata and juvenile idiopathic arthritis. In the United States, baricitinib also has an authorized use for certain hospitalized adults with COVID-19 who require specified levels of respiratory support.
Because approved uses and prescribing requirements can change between countries, patients should use Barigen 4 mg only according to the instructions of a qualified healthcare professional and the applicable local product information.
General Pharmaceuticals Ltd. About the Manufacturer
General Pharmaceuticals Limited (GPL) is a Bangladesh-based pharmaceutical manufacturer focused on developing and producing finished pharmaceutical products. The company has been operating since the 1980s and has developed a broad portfolio of medicines for the domestic and international markets.
Head Office: General Pharmaceuticals Limited. Sara Aftab Tower, 29 Ring Road, Holdings no. 6/1/A, Shyamoli, Adabor, Dhaka-1207.
Holdings no. 6/1/A, 29 Ring Road, Sara Aftab Tower, Adabor Main Rd, Dhaka 1207, Bangladesh
The manufacturer produces medicines across several therapeutic areas and dosage forms. Its facilities include production capabilities for tablets, capsules, oral liquids, ophthalmic products, sterile products, injectables, large-volume parenterals, and other pharmaceutical formulations.
Barigen 4 mg is identified as a baricitinib product manufactured by General Pharmaceuticals Ltd.
Manufacturer information is important when verifying a medicine because different companies may produce products containing the same active ingredient.
Patients and healthcare professionals should verify the product name, strength, batch information, manufacturer, and applicable registration details before use.
What is Barigen 4 mg?
Barigen 4 mg is a tablet containing 4 mg of baricitinib. Public product information identifies Barigen 4 mg as a baricitinib product manufactured by General Pharmaceuticals Ltd.
Baricitinib belongs to a class of medicines known as Janus kinase inhibitors, or JAK inhibitors. JAK enzymes are involved in transmitting signals from several cytokines and other signaling molecules that regulate immune and inflammatory responses.
By inhibiting JAK activity, baricitinib can reduce signaling through selected inflammatory pathways. This pharmacological effect can help control inflammation and abnormal immune activity in certain diseases.
Barigen 4 mg is a prescription medicine and should be used under appropriate medical supervision.
What is baricitinib?
Baricitinib is an oral small-molecule JAK inhibitor. It is classified as an immunomodulatory medicine because it modifies signaling involved in immune-system and inflammatory responses.
Unlike many biologic medicines, which are generally administered by injection or infusion, baricitinib is administered orally.
The medicine selectively inhibits JAK1 and JAK2. These enzymes participate in intracellular signaling pathways activated by various cytokines. By reducing activity in these pathways, baricitinib can influence inflammatory and immune responses.
The clinical effect of baricitinib depends on the disease being treated, the patient’s individual characteristics and the prescribed treatment regimen.
Baricitinib originator and reference product
The originator/reference medicine associated with baricitinib is Olumiant, a branded medicine containing the active ingredient baricitinib.
Baricitinib was developed through research involving Incyte Corporation, with Eli Lilly and Company collaborating in its development and commercialization. In the European Union, Olumiant received marketing authorization in February 2017, and the current EU marketing authorization holder is Eli Lilly Nederland B.V.
Olumiant contains the same active pharmaceutical ingredient, baricitinib, that is used in Barigen 4 mg. However, Barigen is a separate product manufactured by General Pharmaceuticals Ltd.
A generic or branded-generic product should not be described as being manufactured by the originator company unless that company is actually responsible for manufacturing the specific product. Product manufacturer, registration status, formulation, packaging and availability may differ between countries.
What is Olumiant?
Olumiant is the branded medicine containing baricitinib that serves as an important reference product for baricitinib therapy. The European Medicines Agency identifies Olumiant as containing baricitinib and lists Eli Lilly Nederland B.V. as its marketing authorization holder in the European Union.
Olumiant was initially authorized in the EU for adults with moderate-to-severe active rheumatoid arthritis who had an inadequate response to, or could not tolerate, certain disease-modifying antirheumatic drugs. Its European authorization has subsequently included additional indications.
The existence of an originator product does not mean that every baricitinib product has identical regulatory status in every country. Patients should check the authorization applicable to the product and country concerned.
How does Barigen 4 mg work?
Barigen 4 mg works through its active ingredient, baricitinib.
JAK enzymes are intracellular proteins involved in transmitting signals from cytokines. Some cytokines contribute to inflammation and immune-system activation.
Baricitinib inhibits JAK1 and JAK2 activity. This reduces signaling through selected pathways and can decrease inflammatory activity.
The mechanism can be summarized as:
Cytokine signaling → JAK activation → downstream immune signaling → inflammation
Baricitinib:
JAK inhibition → reduced selected cytokine signaling → modulation of inflammatory and immune activity
The precise clinical effect differs depending on the underlying condition and the patient’s response to treatment.
What conditions can baricitinib treat?
The approved indications for baricitinib differ by jurisdiction.
Rheumatoid arthritis
Baricitinib is authorized in certain jurisdictions for adults with moderate-to-severe active rheumatoid arthritis when previous disease-modifying antirheumatic drug treatment has not produced an adequate response or cannot be tolerated.
In the EU, Olumiant may be used alone or together with methotrexate in appropriately selected patients.
Atopic dermatitis
Baricitinib is authorized in the EU for moderate-to-severe atopic dermatitis in adults and pediatric patients from 2 years of age who are candidates for systemic therapy.
The exact age requirements and treatment criteria depend on the local authorization.
Alopecia areata
Baricitinib is also used for severe alopecia areata in certain patients.
In the EU, the authorized indication includes adults and adolescents from 12 years of age with severe alopecia areata.
Juvenile idiopathic arthritis
Current EU authorization includes baricitinib for selected patients aged 2 years and older with active juvenile idiopathic arthritis who have had an inadequate response to, or intolerance of, specified previous disease-modifying antirheumatic treatments. The authorization covers specified forms of juvenile idiopathic arthritis.
COVID-19
Baricitinib has also been authorized in the United States for certain hospitalized adults with COVID-19 who require specified levels of respiratory support.
COVID-19 authorization should not be assumed to apply in every country. Regulatory status and treatment recommendations vary by jurisdiction.
Barigen 4 mg dosage
The appropriate dose of baricitinib depends on the medical condition being treated, the patient’s age, kidney function, other medical conditions, concomitant medicines and the applicable prescribing information.
Although this product contains 4 mg of baricitinib, the presence of a 4 mg tablet does not mean that every patient should take 4 mg.
Patients should follow the dosage prescribed by their healthcare professional.
Do not increase, reduce or stop the dose without medical advice.
How to take Barigen 4 mg
Barigen 4 mg is intended for oral administration.
Take the medicine exactly as prescribed.
Depending on the applicable product information, baricitinib may be taken with or without food. Patients should follow the instructions supplied with their specific product.
If a dose is missed, patients should follow the instructions provided by their healthcare professional or product information rather than taking extra tablets to compensate.
Do not take more Barigen 4 mg than prescribed.
Barigen 4 mg and kidney function
Kidney function can affect baricitinib exposure in the body.
Patients with reduced kidney function may require a different dosage or may not be appropriate candidates for treatment depending on the severity of renal impairment and the indication.
Healthcare professionals may assess kidney function before and during treatment.
Patients should tell their doctor if they have kidney disease or have previously been told that their kidney function is reduced.
Important safety information
Baricitinib affects immune-system signaling and can increase the risk of certain adverse effects.
Important safety considerations include:
Serious infections
Tuberculosis
Other opportunistic infections
Malignancies
Major adverse cardiovascular events
Thrombosis
Changes in blood-cell counts
Changes in liver or lipid laboratory values
Hypersensitivity reactions
Gastrointestinal perforation in appropriate clinical circumstances
JAK inhibitors have important safety warnings, and treatment decisions should take individual risk factors into account.
Patients should contact their healthcare professional promptly if they develop symptoms suggesting a serious infection or another significant adverse reaction.
Serious infections
Because baricitinib modifies immune-system activity, it may increase susceptibility to infections.
Patients should tell their healthcare professional if they have an active infection or a history of recurrent infections.
Tuberculosis screening may be required before treatment, depending on local prescribing recommendations and the patient’s risk factors.
Patients should seek medical attention for concerning symptoms such as persistent fever, severe cough, unexplained weakness or other symptoms of a serious infection.
Blood clots
JAK inhibitors, including baricitinib, have been associated with thrombotic events in certain patients.
Patients with risk factors for blood clots should discuss those risks with their healthcare professional before treatment.
Urgent medical evaluation may be necessary if symptoms suggest a blood clot, such as sudden chest pain, difficulty breathing or unexplained swelling and pain in an extremity.
Cardiovascular considerations
Some patients receiving JAK inhibitors may have an increased risk of major cardiovascular events.
The overall risk depends on factors such as age, smoking status, cardiovascular disease, blood pressure, cholesterol levels and other medical conditions.
Healthcare professionals should consider individual cardiovascular risk when deciding whether baricitinib is appropriate.
Malignancy considerations
Medicines that modify immune-system activity may affect the risk of certain malignancies.
Patients should discuss their individual cancer risk with their healthcare professional, particularly if they have a history of cancer or other significant risk factors.
Routine medical follow-up should be maintained during treatment.
Laboratory monitoring
Depending on the patient’s circumstances, healthcare professionals may monitor:
Complete blood counts
Kidney function
Liver function
Lipid levels
Signs of infection
Other laboratory parameters considered clinically appropriate
The frequency of monitoring depends on the patient’s condition and treatment plan.
Barigen 4 mg side effects
Like other prescription medicines, Barigen 4 mg may cause side effects.
Potential adverse reactions associated with baricitinib can include:
Upper respiratory tract infections
Headache
Nausea
Acne
Increased cholesterol levels
Changes in blood counts
Liver enzyme abnormalities
Herpes zoster
Other infections
More serious reactions can also occur.
The risk of an adverse reaction varies according to the patient’s health, dose, duration of treatment, other medicines and underlying disease.
This is not a complete list of possible side effects. Patients should read the product information supplied with their medicine and contact a healthcare professional about concerning symptoms.
Who should be cautious with Barigen 4 mg?
Before starting treatment, tell your healthcare professional if you have:
An active or recurrent infection
Tuberculosis or a history of tuberculosis exposure
Kidney disease
Liver disease
A history of blood clots
Cardiovascular disease
Risk factors for cardiovascular disease
A history of cancer
Abnormal blood counts
Gastrointestinal problems
A history of allergic reactions to medicines
Any condition affecting the immune system
Also provide a complete list of prescription medicines, over-the-counter medicines, vitamins and supplements you take.
Barigen 4 mg and other medicines
Baricitinib can interact with other medicines or may require additional monitoring when used with certain treatments.
Tell your healthcare professional about all medicines you use.
Particular attention may be required when baricitinib is combined with other medicines that affect the immune system.
Do not start or stop another prescription medicine without discussing it with your healthcare professional.
Barigen 4 mg during pregnancy
Pregnancy considerations should be discussed with a qualified healthcare professional before using baricitinib.
Patients who are pregnant, planning pregnancy or who become pregnant while taking Barigen 4 mg should contact their healthcare professional for individualized advice.
Barigen 4 mg and breastfeeding
Patients who are breastfeeding or planning to breastfeed should discuss baricitinib treatment with their healthcare professional.
The decision to use the medicine during breastfeeding should be based on the applicable prescribing information and an assessment of the potential benefits and risks.
Barigen 4 mg storage
Store Barigen 4 mg according to the storage instructions provided on the product packaging and official product information.
Keep medicines out of the reach of children.
Do not use tablets after the expiration date shown on the packaging.
If you are unsure how to store or dispose of the medicine, ask a pharmacist.
Barigen 4 mg vs. Olumiant
Barigen 4 mg and Olumiant contain the same active pharmaceutical ingredient, baricitinib.
The key difference is the product and manufacturer.
| Feature | Barigen 4 mg | Olumiant |
|---|---|---|
| Active ingredient | Baricitinib | Baricitinib |
| Strength discussed | 4 mg | Available in authorized strengths/formulations depending on market |
| Product type | Baricitinib product | Reference/originator branded product |
| Manufacturer / company | General Pharmaceuticals Ltd. | Eli Lilly / applicable marketing authorization holder |
| Administration | Oral | Oral |
| Drug class | JAK inhibitor | JAK inhibitor |
Product authorization, formulation, excipients, packaging and availability can vary between markets.
Why is the originator information important?
Understanding the originator product can help patients distinguish between the active pharmaceutical ingredient and individual branded products.
Baricitinib is the active ingredient.
Olumiant is the established branded product containing baricitinib.
Barigen 4 mg is a separate baricitinib product containing 4 mg of the active ingredient.
The manufacturer of a particular product should always be verified from its packaging and official regulatory documentation.
General Pharmaceuticals Ltd. Verification Process
Scan the QR code printed on the product box. The QR code will take you to the official General product verification page, where you can complete the verification process.
The QR code will direct you to the General Pharmaceuticals Ltd., E-Verification page, where you can complete the product verification process.
After completing the verification, check the result carefully to confirm whether the product is genuine.
If the verification indicates that the product is fake or unauthorized, do not use it. Report the suspected counterfeit product and take appropriate legal action against the supplier through the Directorate General of Drug Administration (DGDA), World.
Always purchase medicines from licensed pharmacies or authorized suppliers and verify the product before use.
How to order Barigen 4 mg
If Barigen 4 mg is legally available for purchase in your country, customers should provide the requested product information and follow the applicable ordering process.
Before placing an order, confirm:
The medicine name and strength.
The quantity required.
The delivery destination.
Any prescription or documentation required by local law.
The applicable shipping and payment terms.
Medicines should be purchased only through lawful and appropriate channels.
Order Barigen 4 mg
To inquire about Barigen 4 mg, customers can contact the pharmacy or supplier through the available communication channels.
Before ordering, confirm product availability, packaging, manufacturer information and the requirements applicable to your country.
A prescription may be required depending on the patient’s location and local regulations.
Clinical information about baricitinib
Baricitinib has been evaluated in clinical studies across several inflammatory and immune-mediated diseases.
For rheumatoid arthritis, clinical studies have demonstrated improvements in disease activity and symptoms in appropriately selected patients whose previous disease-modifying treatments were insufficient. The EMA reports that studies involving approximately 2,500 patients contributed to the assessment of Olumiant for rheumatoid arthritis.
The clinical evidence and regulatory authorization for other conditions depend on the specific indication and patient population.
Clinical evidence should not be interpreted as a recommendation for an individual patient. Treatment decisions should be made by a qualified healthcare professional.
Frequently Asked Questions
What is Barigen 4 mg?
Barigen 4 mg is a baricitinib product containing 4 mg of baricitinib, an oral JAK inhibitor.
What is baricitinib?
Baricitinib is a small-molecule JAK inhibitor that modifies signaling pathways involved in inflammation and immune-system activity.
What is Barigen 4 mg used for?
The appropriate use depends on the indication authorized in the patient’s country and the individual patient’s medical circumstances. Baricitinib has authorized uses in certain jurisdictions for conditions including rheumatoid arthritis, atopic dermatitis, severe alopecia areata and juvenile idiopathic arthritis.
What is the originator of baricitinib?
The established branded reference product containing baricitinib is Olumiant. Its development involved Incyte Corporation and Eli Lilly and Company.
Who developed baricitinib?
Baricitinib was developed through research involving Incyte Corporation, with Eli Lilly and Company collaborating in development and commercialization.
Who manufactures Barigen 4 mg?
Barigen 4 mg is identified as being manufactured by General Pharmaceuticals Ltd.
Is Barigen 4 mg the same as Olumiant?
Both contain the active ingredient baricitinib, but they are different branded products. Barigen 4 mg is manufactured by General Pharmaceuticals Ltd., while Olumiant is the established reference product associated with Eli Lilly.
Is Barigen 4 mg a JAK inhibitor?
Yes. Baricitinib, the active ingredient in Barigen 4 mg, is a JAK inhibitor that inhibits JAK1 and JAK2 signaling.
Can I take Barigen 4 mg without a prescription?
Baricitinib is a prescription medicine. Whether a prescription is legally required depends on the country, but patients should use it only under appropriate medical supervision.
Can Barigen 4 mg treat rheumatoid arthritis?
Baricitinib is authorized for selected patients with moderate-to-severe active rheumatoid arthritis in certain jurisdictions. Treatment suitability depends on previous therapy and individual patient factors.
Can baricitinib be used for alopecia areata?
Baricitinib is authorized for severe alopecia areata in certain jurisdictions. The authorized age range and treatment criteria vary by country. In the EU, the indication includes adults and adolescents aged 12 years and older.
Can baricitinib be used for atopic dermatitis?
Yes, baricitinib has an EU authorization for moderate-to-severe atopic dermatitis in adults and pediatric patients aged 2 years and older who are candidates for systemic therapy.
Does Barigen 4 mg have side effects?
Yes. Baricitinib can cause side effects, ranging from relatively common reactions to potentially serious infections and other complications. Patients should review the official product information and discuss individual risks with a healthcare professional.
How should I take Barigen 4 mg?
Take Barigen 4 mg exactly as prescribed. The appropriate dose and treatment schedule depend on the indication, age, kidney function and other patient-specific factors.
Can I stop taking Barigen 4 mg?
Do not stop treatment without discussing it with your healthcare professional. Abruptly changing treatment may affect management of the underlying condition.
References and regulatory information
For reliable information about baricitinib and Olumiant, consult the applicable national medicines regulator and official product information.
The European Medicines Agency identifies Olumiant as a medicine containing baricitinib and records its EU marketing authorization from 13 February 2017.
Regulatory approvals, indications, warnings and age restrictions can change over time. Always use the current product information applicable to your country.
About Barigen
Barigen.com provides educational information about Barigen 4 mg (baricitinib), including information about its active ingredient, mechanism of action, potential uses, safety considerations, manufacturer and product verification.
The website is intended to help readers understand general information about the medicine. It does not replace a consultation with a qualified doctor, pharmacist or other healthcare professional.
Medical Disclaimer
The information provided on Barigen.com is for general educational and informational purposes only. It is not intended to replace professional medical advice, diagnosis or treatment.
Baricitinib is a prescription medicine that can cause serious adverse effects and may not be appropriate for everyone. Treatment decisions should be made by a qualified healthcare professional after considering the patient’s medical history, current medicines, laboratory results and individual risk factors.
Do not start, stop or change Barigen 4 mg treatment without professional medical advice.
Always refer to the official prescribing information and regulatory requirements applicable in your country.